Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus pembrolizumab plus placebo
pembrolizumab plus ipilimumab
KEYNOTE-598, 2020
  NCT03302234
RCTmNSCLC - L1 - PDL1 positivepembrolizumab plus ipilimumabplacebo plus pembrolizumabas first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 with a tumor proportion score (TPS) ≥50% and no EGFR or ALK aberrations284 / 284low
inconclusive
  • inconclusive 8 % increase in deaths (OS) (PE)
  • inconclusive 6 % increase in progression or deaths (PFS) (PE)